Play all audios:
In the wake of a startling deal in which Allergan (AGN) is selling some patents to a Native American tribe, an attorney for the tribe indicated other drug makers have asked about such
arrangements. “I can’t provide specific information, but your assumptions are pretty correct” that representatives for other pharmaceutical companies have made inquiries since the deal was
announced last Friday, said Chris Evans of the Shore Chan DePumpo law firm, which brought the deal to the tribe. This is not surprising. The deal, which involves patents for the best-selling
Restasis eye drops, allows Allergan to avoid a particular type of patent challenge — called inter partes reviews — because the St. Regis Mohawk tribe has sovereign immunity from such
claims. And Allergan hopes to circumvent a challenge from three generic drug makers over Restatis patents, even as it awaits a ruling in a conventional lawsuit challenging its patents filed
by the same companies. STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM
EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe